Retension Pharmaceuticals, Inc. RTSN
IPO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 846.90K | 736.80K | 421.20K | 421.20K | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 4.29M | 3.50M | 2.39M | 2.39M | |
| Operating Income | -4.29M | -3.50M | -2.39M | -2.39M | |
| Income Before Tax | -4.17M | -3.35M | -2.21M | -2.21M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -4.17M | -3.35M | -2.21M | -2.21M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -4.17M | -3.35M | -2.21M | -2.21M | |
| EBIT | -4.29M | -3.50M | -2.39M | -2.39M | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | -5.16 | -4.16 | -2.74 | -2.74 | |
| Normalized Basic EPS | -3.23 | -2.60 | -1.71 | -1.71 | |
| EPS Diluted | -5.16 | -4.16 | -2.74 | -2.74 | |
| Normalized Diluted EPS | -3.23 | -2.60 | -1.71 | -1.71 | |
| Average Basic Shares Outstanding | 807.50K | 806.50K | 805.20K | 805.20K | |
| Average Diluted Shares Outstanding | 807.50K | 806.50K | 805.20K | 805.20K | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |